Mobile

A multi-center, randomized, double-blind, placebo-controlled phase III trial comparing the efficacy of bevacizumab in combination with rituximab and CHOP (RA-CHOP) versus rituximab and CHOP (R-CHOP) i...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-005520-16

A multi-center, randomized, double-blind, placebo-controlled phase III trial comparing the efficacy of bevacizumab in combination with rituximab and CHOP (RA-CHOP) versus rituximab and CHOP (R-CHOP) in previously untreated patients with CD20-positive diffuse large B-cell lymphoma (DLBCL)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• To demonstrate superior clinical efficacy as measured by progression free survival (PFS) of bevacizumab in combination with rituximab and CHOP (RA-CHOP) versus R-CHOP alone for the treatment of previously untreated patients with diffuse large B cell lymphoma (DLBCL) with at least low-intermediate risk disease according to the IPI or bulky disease regardless of IPI risk category.

Critère d'inclusion

  • Previously untreated CD20-positive Diffuse Large B-Cell Lymphoma (DLBCL) patients

Liens